Wall Street Has a Positive Opinion on ​PROCEPT BioRobotics (PRCT), Here’s Why

​Recently, connected January 26, Ryan Zimmerman from BTIG maintained a Hold standing connected the banal without disclosing immoderate terms targets. Earlier connected December 18, Richard Newitter from Truist Financial reiterated a Buy standing connected the stock, but lowered the terms people from $50 to $47.

​Analysts astatine Truist noted that they stay optimistic connected the MedTech assemblage successful 2026, chiefly owed to its charismatic valuation compared to different healthcare areas. However, the terms people simplification reflects the interest that the assemblage could go a root alternatively than the destination of caller healthcare investments. The steadfast besides highlighted that they similar companies successful the MedTech assemblage which contiguous catalysts for durable maturation successful 2026.

​That said, Wall Street’s 12-month mean terms people reflects much than 77% upside from the existent levels and 79% of the 14 analysts covering the banal support a Buy standing connected PROCEPT BioRobotics Corporation (NASDAQ:PRCT).

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is simply a commercial-stage institution specializing successful surgical robotics solutions for urology. The AquaBeam Robotic System is the company’s flagship merchandise with an precocious image-guided strategy designed for minimally-invasive urologic surgeries.

While we admit the imaginable of PRCT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.